肺动脉高压是一种相对少见但有潜在致命危险的疾病,多年来缺乏有效治疗药物。最近,美国FDA批准西地那非口服制剂Revatio可用于治疗肺动脉高压,为肺动脉高压患者的治疗带来了新的希望。本文就西地那非治疗肺动脉高压的机理,临床疗效及安全性等作一综述。 Pulmonary hypertension is a relatively rare but potentially fatal disease that lacks an effective treatment for many years. Recently, the United States FDA approved Revatio, an oral formulation of sildenafil, for the treatment of pulmonary hypertension, offering new hope for the treatment of patients with pulmonary hypertension. This article reviews the mechanism, clinical efficacy and safety of sildenafil in the treatment of pulmonary hypertension.